SCHEMBL2831670

SCHEMBL2831670

CC=CN1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2831669 1.00
SCHEMBL13292040 1.00
SCHEMBL1601391 0.97
SCHEMBL1601393 0.97
SCHEMBL4920092 0.97
SCHEMBL9545869 0.86
SCHEMBL12551207 0.77 RAB9A (0.33)
SCHEMBL28381006 0.77 ALDH1A1 (0.33)
SCHEMBL9911061 0.75 L3MBTL3 (0.41)
SCHEMBL13960775 0.75 CYP1A2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116854649-A Gemini quaternary ammonium base type structure directing agent, preparation method thereof, AFX molecular sieve, preparation method thereof and application thereof 华东理工大学 2023-10-10 CN claimed
US-8957254-B2 Process for chemical synthesis from an alkenone made from a halogenated precursor SOLVAY SA (BE) 2015-02-17 US claimed
US-20140051892-A1 Process for chemical synthesis from an alkenone made from a halogenated precursor SOLVAY SA (BE) 2014-02-20 US claimed
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2026-04-23 US disclosed
US-12569565-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
US-12427200-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2025-09-30 US disclosed
US-20230398226-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-12-14 US disclosed
CN-116854649-A Gemini quaternary ammonium base type structure directing agent, preparation method thereof, AFX molecular sieve, preparation method thereof and application thereof 华东理工大学 2023-10-10 CN disclosed
CN-115141176-B Acetylenic indole FGFR inhibitor and preparation method and application thereof 药雅科技(上海)有限公司 2023-08-22 CN disclosed
CN-115160397-B Androstane derivatives, preparation method and application thereof 天津红日药业股份有限公司 2023-08-01 CN disclosed
US-11510992-B1 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2022-11-29 US disclosed
EP-1562621-A1 COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISEASES USING PROTEASE INHIBITORS Arriva-Prometic Inc. (CA) 2005-08-17 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed
WO-2004045634-A1 COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISEASES USING PROTEASE INHIBITORS ARRIVA-PROMETIC INC. (CA) 2004-06-03 WO disclosed
WO-2003042149-A1 METHOD FOR PRODUCTION OF N-BUTYRALDEHYDE AND N-BUTANOL FROM 1,3-BUTADIENE-CONTAINING HYDROCARBON STREAMS BASF AKTIENGESELLSCHAFT (DE) 2003-05-22 WO disclosed
EP-0982293-A1 Process for the preparation of imines and enamines, and possibly their further hydrogenation into amines BASF AKTIENGESELLSCHAFT (DE) 2000-03-01 EP disclosed
EP-0778819-A1 PROCESS FOR PRODUCING N-BUTYRALDEHYDE AND/OR N-BUTANOL BASF AKTIENGESELLSCHAFT (DE) 1997-06-18 EP disclosed
WO-1996007630-A1 PROCESS FOR PRODUCING N-BUTYRALDEHYDE AND/OR N-BUTANOL BASF AKTIENGESELLSCHAFT (DE) 1996-03-14 WO disclosed
US-4324792-A SKIN DISORDERS, HAY FEVER, ASTHMA GLAXO GROUP LIMITED (GB) 1982-04-13 US disclosed
US-4238609-A Production of ampho-ionic compounds NIPPON PAINT CO., LTD. (JP) 1980-12-09 US disclosed